TrialProstate cancer and prostatic diseases2020

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.

Risa L Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.